SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). Despite the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Gao, Min, Huang, Zhaoqin, Yu, Jinming, Meng, Xiangjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390199/
https://www.ncbi.nlm.nih.gov/pubmed/32723363
http://dx.doi.org/10.1186/s13045-020-00940-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390199/
https://www.ncbi.nlm.nih.gov/pubmed/32723363
http://dx.doi.org/10.1186/s13045-020-00940-z

Ejemplares similares